Medicus Pharma Ltd. has announced the pricing of its public offering, raising $7.0 million through the issuance of 2,260,000 units at $3.10 per unit. Each unit includes one common share and one warrant, which can be exercised to purchase an additional common share at the same price within five years. The offering is led by Maxim Group LLC, with Brookline Capital Markets and D. Boral Capital as co-placement agents. The common shares are listed on NASDAQ under the symbol "MDCX," while the warrants will not be traded on any securities exchange. Proceeds from this offering are earmarked for advancing the company's clinical trials related to basal cell carcinoma and potentially expanding trials to other non-melanoma skin diseases, with remaining funds allocated for general corporate purposes.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.